Biotech Startup ImmunOs Therapeutics AG Raises CHF 15M in Series A Financing

10.12.2019 09:00, Gianmaria Sbetta

Schlieren-based biotech startup and leading developer of a next-generation innate immunity focused immunotherapy platform for cancer, announced the closing of a Series A financing round of CHF 15 million.

ImmunOs Therapeutics AG is a biotechnology company active in the discovery and development of the next generation of novel human immunomodulatory proteins focused on innate immunity. Originally a spin-off of the University of Zurich and the University of Basel, the company announced today the closing of a CHF 15 million Series A financing round co-led by Pfizer Ventures and BioMedPartners with the participation of Redalpine, Schroder Adveq, Wille Finance AG, BERNINA BioInvest Ltd alongside new private and existing investors. 

Company's founder and CSO Osiris Marroquin Belaunzaran, participated in 2008 in the Venture Challenge courses and started his entrepreneurial journey with the support of Venturelab.